傅源 - 天津医科大学

个人简介

教育背景 2004.08-2008.07 清华大学化学学士 2008.08-2012.07 美国伊利诺伊大学厄巴纳香槟分校化学博士工作经历 2019.01至今天津医科大学基础医学院药理系，教授 2017.12-2018.12 天津医科大学基础医学院药理系，副教授 2012.08-2017.02 美国康奈尔大学化学与化学生物学系，博士后荣誉奖励 2018 天津市131人才，第二层次

研究领域

肿瘤细胞代谢、细胞周期调控、化学生物学工具的开发

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Fu, Y.#; Long, M. J.#; Wisitpitthaya, S.; Inayat, H.; Pierpont, T. M.; Bloom, J. C.; Ortega, J.; Weiss, R. S.; Aye, Y.* Nuclear RNR-α Antagonizes Cell Proliferation by Directly Inhibiting ZRANB3 Nat. Chem. Biol. 2018, 14, 943-954　(IF:13.843) 2. Parvez, S.#; Fu, Y.#; Li, J.; Long, M. J.; Lin, H. Y.; Lee, D. K.; Hu, G. S.; Aye, Y.*, Substoichiometric hydroxynonenylation of a single protein recapitulates whole-cell-stimulated antioxidant response. J Am Chem Soc 2015, 137 (1), 10-3 (IF:13.038) 3. Fu, Y.; Lin, H. Y.; Wisitpitthaya, S.; Blessing, W. A.; Aye, Y.*, A fluorimetric readout reporting the kinetics of nucleotide-induced human ribonucleotide reductase oligomerization. Chembiochem 2014, 15 (17), 2598-604. (IF:3.162) 4. Fu, Y.; Long, M. J.; Rigney, M.; Parvez, S.; Blessing, W. A.; Aye, Y.*, Uncoupling of allosteric and oligomeric regulation in a functional hybrid enzyme constructed from Escherichia coli and human ribonucleotide reductase.　Biochemistry 2013, 52 (40), 7050-9 (IF:3.104) 5. Fang, X.#; Fu, Y.#; Long, M. J.; Haegele, J. A.; Ge, E. J.; Parvez, S.; Aye, Y.*, Temporally controlled targeting of 4- hydroxynonenal to specific proteins in living cells. J Am Chem Soc 2013, 135 (39), 14496-9 (IF: 11.444) 6. Fu, Y.; Ramisetty, S. R.; Hussain, N.; Baranger, A. M.* MBNL1–RNA Recognition: Contributions of MBNL1 Sequence and RNA Conformation. ChemBioChem, 2012 13, 112-9 (IF: 3.740) 7. Jahromi, A. H.; Fu, Y.; Miller, K. A.; Nguyen, L.; Luu, L. M.; Baranger, A. M.*; Zimmerman, S. C.*, Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1. J Med Chem 2013, 56 (23), 9471-81 (IF:5.504) 8. Jahromi, A. H.; Nguyen, L.; Fu, Y.; Miller, K. A.; Baranger, A. M.*; Zimmerman, S. C.*, A novel CUG(exp).MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. ACS Chem Biol 2013, 8 (5), 1037-43 (IF:9.062) 9. Wong, C. H.; Fu, Y.; Ramisetty, S. R.; Baranger, A. M.*; Zimmerman, S. C.*, Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2). Nucleic Acids Res 2011, 39(20), 8881-90(IF:7.417) 10. Huang, C.; Fu, Y.; Fu, H.*; Jiang, Y.; Zhao, Y., Highly efficient copper-catalyzed cascade synthesis of quinazoline and quinazolinone derivatives. Chem Commun 2008, (47), 6333-5(IF:4.997)